The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-κB pathway

Raffaella Dell'Eva, Simona Minghelli, Simona Minghelli, Douglas M. Noonan, Adriana Albini, Nicoletta Ferrari

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Several natural compounds, especially plant products and dietary constituents, are able to exhibit 'angiopreventive' (anti-angio genic chemo prevention) activities both in vitro and in vivo. Deguelin is a rotenoid of the flavonoid family with chemopreventive activities able to decrease tumor incidence in animal models for lung, colon, mammary and skin carcinogenesis through Akt inhibition. Here we show that deguelin belongs to the 'angiopreventive' molecules and provide evidence for molecular events associated with its anti-angiogenic properties. The data show that deguelin inhibits HUVE cells growth by inducing cell-cycle arrest in the G0/G1 phase and in the absence of apoptosis. Growth arrest is associated with induction of p21 and p53 and decreased survivin levels. Deguelin also interferes with several points in the angiogenic process, including inhibition of endothelial cell migration, invasion and metalloprotease production, and potently inhibits in vivo angiogenesis and vascular tumor growth. In addition to Akt, the nuclear factor-kappaB (NF-κB) kinase pathway, which plays a critical role in the regulation of inflammation, vascular homeostasis and angiogenesis, was also repressed by deguelin even in the presence of inflammatory stimuli such as tumor necrosis factor-α (TNF-α). These findings reveal a new therapeutic potential for deguelin in angioprevention and anti-angiogenic therapy.

Original languageEnglish
Pages (from-to)404-413
Number of pages10
JournalCarcinogenesis
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Blood Vessels
Growth
Cell Cycle Resting Phase
G1 Phase
Metalloproteases
Cell Cycle Checkpoints
Flavonoids
Cell Movement
deguelin
Neoplasms
Colon
Carcinogenesis
Breast
Homeostasis
Phosphotransferases
Endothelial Cells
Animal Models
Tumor Necrosis Factor-alpha
Apoptosis
Inflammation

ASJC Scopus subject areas

  • Cancer Research

Cite this

The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-κB pathway. / Dell'Eva, Raffaella; Minghelli, Simona; Minghelli, Simona; Noonan, Douglas M.; Albini, Adriana; Ferrari, Nicoletta.

In: Carcinogenesis, Vol. 28, No. 2, 02.2007, p. 404-413.

Research output: Contribution to journalArticle

@article{0f9f1d1ca8eb4cc0a42e36792047b9e2,
title = "The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-κB pathway",
abstract = "Several natural compounds, especially plant products and dietary constituents, are able to exhibit 'angiopreventive' (anti-angio genic chemo prevention) activities both in vitro and in vivo. Deguelin is a rotenoid of the flavonoid family with chemopreventive activities able to decrease tumor incidence in animal models for lung, colon, mammary and skin carcinogenesis through Akt inhibition. Here we show that deguelin belongs to the 'angiopreventive' molecules and provide evidence for molecular events associated with its anti-angiogenic properties. The data show that deguelin inhibits HUVE cells growth by inducing cell-cycle arrest in the G0/G1 phase and in the absence of apoptosis. Growth arrest is associated with induction of p21 and p53 and decreased survivin levels. Deguelin also interferes with several points in the angiogenic process, including inhibition of endothelial cell migration, invasion and metalloprotease production, and potently inhibits in vivo angiogenesis and vascular tumor growth. In addition to Akt, the nuclear factor-kappaB (NF-κB) kinase pathway, which plays a critical role in the regulation of inflammation, vascular homeostasis and angiogenesis, was also repressed by deguelin even in the presence of inflammatory stimuli such as tumor necrosis factor-α (TNF-α). These findings reveal a new therapeutic potential for deguelin in angioprevention and anti-angiogenic therapy.",
author = "Raffaella Dell'Eva and Simona Minghelli and Simona Minghelli and Noonan, {Douglas M.} and Adriana Albini and Nicoletta Ferrari",
year = "2007",
month = "2",
doi = "10.1093/carcin/bgl162",
language = "English",
volume = "28",
pages = "404--413",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-κB pathway

AU - Dell'Eva, Raffaella

AU - Minghelli, Simona

AU - Minghelli, Simona

AU - Noonan, Douglas M.

AU - Albini, Adriana

AU - Ferrari, Nicoletta

PY - 2007/2

Y1 - 2007/2

N2 - Several natural compounds, especially plant products and dietary constituents, are able to exhibit 'angiopreventive' (anti-angio genic chemo prevention) activities both in vitro and in vivo. Deguelin is a rotenoid of the flavonoid family with chemopreventive activities able to decrease tumor incidence in animal models for lung, colon, mammary and skin carcinogenesis through Akt inhibition. Here we show that deguelin belongs to the 'angiopreventive' molecules and provide evidence for molecular events associated with its anti-angiogenic properties. The data show that deguelin inhibits HUVE cells growth by inducing cell-cycle arrest in the G0/G1 phase and in the absence of apoptosis. Growth arrest is associated with induction of p21 and p53 and decreased survivin levels. Deguelin also interferes with several points in the angiogenic process, including inhibition of endothelial cell migration, invasion and metalloprotease production, and potently inhibits in vivo angiogenesis and vascular tumor growth. In addition to Akt, the nuclear factor-kappaB (NF-κB) kinase pathway, which plays a critical role in the regulation of inflammation, vascular homeostasis and angiogenesis, was also repressed by deguelin even in the presence of inflammatory stimuli such as tumor necrosis factor-α (TNF-α). These findings reveal a new therapeutic potential for deguelin in angioprevention and anti-angiogenic therapy.

AB - Several natural compounds, especially plant products and dietary constituents, are able to exhibit 'angiopreventive' (anti-angio genic chemo prevention) activities both in vitro and in vivo. Deguelin is a rotenoid of the flavonoid family with chemopreventive activities able to decrease tumor incidence in animal models for lung, colon, mammary and skin carcinogenesis through Akt inhibition. Here we show that deguelin belongs to the 'angiopreventive' molecules and provide evidence for molecular events associated with its anti-angiogenic properties. The data show that deguelin inhibits HUVE cells growth by inducing cell-cycle arrest in the G0/G1 phase and in the absence of apoptosis. Growth arrest is associated with induction of p21 and p53 and decreased survivin levels. Deguelin also interferes with several points in the angiogenic process, including inhibition of endothelial cell migration, invasion and metalloprotease production, and potently inhibits in vivo angiogenesis and vascular tumor growth. In addition to Akt, the nuclear factor-kappaB (NF-κB) kinase pathway, which plays a critical role in the regulation of inflammation, vascular homeostasis and angiogenesis, was also repressed by deguelin even in the presence of inflammatory stimuli such as tumor necrosis factor-α (TNF-α). These findings reveal a new therapeutic potential for deguelin in angioprevention and anti-angiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=33847259309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847259309&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgl162

DO - 10.1093/carcin/bgl162

M3 - Article

C2 - 16952909

AN - SCOPUS:33847259309

VL - 28

SP - 404

EP - 413

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 2

ER -